ClinicalTrials.gg
RecruitingNCT03994471ELIXIRUpdated Mar 24, 2026

Efficacy and Safety of XyloCore Peritoneal Dialysis Solution.

A Phase 3 interventional study of XyloCore Low Strenght, XyloCore Medium Strenght, XyloCore High Strenght and 1.36%, 1.5%, 2.27%, 2.5%, 3.86%, 2.25% Glucose PD Solution in End Stage Renal Disease, sponsored by Iperboreal Pharma Srl. Recruiting at 41 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-24.

Sponsored by Iperboreal Pharma Srl · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2022; still recruiting 3 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
170
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 75 studies in Kidney Failure, Chronic with a site in Italy — 14 open to participants now, 19 under way, 4 of them phase 3. Kidney Failure, Chronic · Italy.

Planned enrollment
21st of 59
170 · median 80
Started
2022
with 6 others
Phase 3
17 of 75
1 open now
Primary completion
2026-12
later than 5 of 18 live
Registered
48th of 75
by date
Lead sponsor
6 of 75
Iperboreal Pharma Srl

Among the 75 studies in Kidney Failure, Chronic with a site in Italy, this one is the 21st largest by planned enrollment of the 59 interventional ones that give a count, is one of 7 that started in 2022, is one of 17 in phase 3, reaches primary completion later than 5 of the 18 other live ones, and was the 48th registered.

Kidney Failure, Chronic

2,115 studies on the registry are indexed under Kidney Failure, Chronic; 277 are open to participants now.

Browse Kidney Failure, Chronic studies →

Open to participants now

14 of the 75 studies in Kidney Failure, Chronic with a site in Italy are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 170 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 75 studies in Kidney Failure, Chronic with a site in Italy, or all of them as a file.
02

Study summary

Randomized, controlled, parallel groups, open-label, blinded end-point assessment, multicenter study, comparing the effects of a low glucose peritoneal dialysis solution, XyloCore, to glucose solutions (Physioneal, Fixioneal, Dianeal, Balance, Bicavera, Bicanova or Equibalance) only regimen, in patients with End-Stage Renal Disease (ESRD) receiving Continuous Ambulatory Peritoneal Dialysis (CAPD), over a 6-month study period.

Read the detailed description

Patients should be enrolled if they are receiving 1, 2 or 3 diurnal exchanges of one of the following PD solutions (standard treatment): Physioneal 35 or 40 (including Clear-Flex bag), Fixioneal 35 or 40, Dianeal or Dianeal Low Calcium (1.36%, 2.27% or 3.86% glucose), or Balance, Bicavera, Bicanova or Equibalance (1.5%, 2.3%, 4.25% glucose) - and - one bag of Extraneal (7.5% Icodextrin) for the long-dwell exchange. Patients will be centrally randomized to the investigational product (XyloCore) or the glucose-only PD solution active comparator. Patients randomized to the control group will continue with their prescription of standard treatment with 1, 2 to 3 daily (short-dwell) exchanges of Physioneal, Fixioneal, Dianeal, Balance, Bicavera, Bicanova or Equibalance PD solution. Patients randomized to XyloCore will receive XyloCore Low, Medium or High Strength according to the osmotic strength (glucose concentration) of their prerandomization prescribed PD solution. All patients will keep being prescribed Extraneal (7.5% Icodextrin) for the nocturnal (long-dwell) exchange. The osmotic strength and number of diurnal short dwell exchanges may be modified by the investigator as clinically required. PD prescriptions in both treatment arms should be tailored to reach the minimum target of a total Kt/V of > 1.7 per week throughout the study. A stratified randomization scheme will be employed to ensure balanced allocation across the two treatment groups of patients with diabetes and of patients treated with only 1 diurnal exchange. Randomization will be performed centrally via a web-based system according to a computer-generated randomization list. The study is open-label with blinded evaluator (primary endpoint), without blinding of patients or clinical staff.

03

Conditions studied

  • End Stage Renal Disease

Keywords

  • peritoneal dialysis
  • ESRD
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18 years
  2. Diagnosed with ESRD and treated with CAPD in the last 3 months
  3. In stable clinical condition during the 3 months before screening as demonstrated by the absence of non-elective hospitalization and major cardiovascular events
  4. Have not experienced peritonitis episodes in the last 3 months
  5. In treatment with prescribed Extraneal (nocturnal exchange bag solution) for at least 1 month
  6. In treatment with 1, 2 or 3 diurnal exchange bag solution of prescribed Phisioneal (including Clear-Flex bag), Fixioneal, Dianeal or Dianeal Low Calcium (1.36%, 2.27% or 3.86% glucose), or Balance, Bicavera, Bicanova or Equibalance (1.25%, 2.3%, 4.5% glucose)
  7. Kt/V urea measurement > 1.7 per week at Baseline Visit
  8. Followed/treated by the participating clinical Center/Investigator in the last three months
  9. Understanding the nature of the study and providing their to participation.

Exclusion criteria

EXCLUSION CRITERIA:

  1. History of drug or alcohol abuse in the six months prior to entering the protocol
  2. In treatment with androgens
  3. abnormal liver function test (ɣ-GT > 4 times the upper normal limit)
  4. Acute infectious conditions (i.e.: pulmonary infection, acute hepatitis, high or low urinary tract infections, renal parenchymal infection, pericarditis, etc)
  5. Expected patient's survival shorter than the trial duration
  6. History of L-Carnitine therapy or use in the month prior to entering the protocol
  7. Have used any drug in the 3 months prior to entering the protocol
  8. Female patients who are pregnant or breast-feeding.
  9. Female patients of childbearing age (less than 24 months after the last menstrual cycle) who do not use adequate
  10. Patients affected by Primary Hyperoxaluria as per known medical therapy
  11. Patients with serum levels of uric acid > 7.2 mg/dl (male and women) or > 6.0 mg/dl (premenopausal women)
  12. Patients with a major cardiovascular event in the last 3 months
  13. Patients with advanced cardiac failure ( 4)
  14. to any of the constituents of the study IMPs.
  15. Any to the prescribed Peritoneal Dialysis solutions (for long-dwell and short-dwell exchange) as per each product SmPC.
  16. Participants with medical history of oxalate or lactate abnormalities considered clinically significant by the investigator.
  17. History or evidence of any other medical, neurological or psychological condition that would expose the subject to an undue risk of a significant AE or interfere with study assessments during the course of the trial as determined by the clinical judgment of the investigator.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
170 participants (estimated)

Study arms

  • Experimental
    XyloCore peritoneal dialysis solution

    Patients will receive 1, 2 or 3 daily (short-dwell) exchanges with XyloCore of an osmotic strength comparable to their pre-randomization prescription of glucose peritoneal dialysis solution (XyloCore Low, Medium and High Strenght have an osmotic strength comparable to Physioneal, Fixioneal or Dianeal 1.36%, 2.27%, 3.86% glucose, respectively, and Balance, Bicavera, Bicanova or Equibalance with 1.5%, 2.5%, 4.25% glucose, respectively). All patients will receive Extraneal (7.5% Icodextrin) for nocturnal (long-dwell) exchange.

    Drug: XyloCore Low Strenght, XyloCore Medium Strenght, XyloCore High Strenght

  • Active comparator
    Glucose peritoneal dialysis solution

    Patients randomized to glucose solution will continue the 1, 2 or 3 daily (short-dwell) exchanges of Physioneal 40 or 35, Fixioneal 40 or 35 or Dianeal (1.36%, 2.27%, 3.86% glucose), Balance, Bicavera, Bicanova or Equibalance (1.5%, 2.5%, 4.25% glucose) with the same osmotic strength of their pre-randomization prescription. All patients will receive Extraneal (7.5% Icodextrin) for nocturnal (long-dwell) exchange.

    Drug: 1.36%, 1.5%, 2.27%, 2.5%, 3.86%, 2.25% Glucose PD Solution

Interventions

  • DrugXyloCore Low Strenght, XyloCore Medium Strenght, XyloCore High Strenght

    XyloCore Low Strenght: 0.7% Xylitol, 0.5% Glucose, and 0.02% L-carnitine - or - XyloCore Medium Strenght: 1.5% Xylitol, 0.5% Glucose, and 0.02% L-carnitine - or - XyloCore High Strenght: 2.0% Xylitol, 1.5% Glucose, and 0.02% L-carnitine

    Also known as: XyloCore 0.7 or 1.5 or 2.0

  • Drug1.36%, 1.5%, 2.27%, 2.5%, 3.86%, 2.25% Glucose PD Solution

    Physioneal 35 or 40 (including Clear-Flex bag), Fixioneal 35 or 40, Dianeal or Dianeal Low Calcium have 1.36%, 2.27% or 3.86% glucose; Balance, Bicavera, Bicanova or Equibalance have 1.25%, 2.3%, 4.5% glucose.

    Also known as: Physioneal 40 or 35, Fixioneal 40 or 35, Dianeal, Balance, Bicavera, Bicanova, Equibalance

06

What researchers measure

Primary outcomes

  1. Total weekly Kt/Vurea

    To measure solutes and calculate peritoneal and renal Kt/V (summing up to total Kt/V), dialysate outflow and urine covering 24 hours will be collected, the volumes will be determined, and a blood sample will be taken

    Time frame: 24-week

Secondary outcomes

  1. Changes in HbA1c (glycated haemoglobin)

    Change from baseline value

    Time frame: 6 months

  2. Insulin

    Changes from the baseline value

    Time frame: 6 months

  3. LDL cholesterol

    Changes from the baseline value

    Time frame: 6 months

  4. HDL cholesterol

    Change from the baseline value

    Time frame: 6 months

  5. Serum triglycerides

    Change from the baseline value

    Time frame: 6 months

  6. Total cholesterol

    Changes from the baseline

    Time frame: 6 months

  7. Hemoglobin

    Changes from the baseline value

    Time frame: 6 months

  8. EPO requirements

    Change from the baseline

    Time frame: 6 months

  9. Fatigue measured through a validated instrument

    Changes from the baseline

    Time frame: 6 months

  10. Peritoneal ultrafiltration

    Changes from baseline

    Time frame: 6 months

  11. Diuresis (or 24 hours urinary volume)

    Changes from baseline

    Time frame: 6 months

  12. Residual renal function

    Changes from baseline - measured as the arithmetic mean of urinary urea and creatinine clearance

    Time frame: 6 months

  13. Adverse Events

    Information about all adverse events, whether volunteered by the patient, discovered by investigator questioning, or detected through physical examination, laboratory test or other means, will be collected, recorded and followed as appropriate.

    Time frame: 6 months

07

Study locations

33 of 41 sites recruiting
  • Aalborg University
    Aalborg, Denmark
    Not yet recruiting
    • Hanna Sofia Svensson, MD · Contact
  • Aarhus University Hospital
    Aarhus, Denmark
    Recruiting
    • Johan Povlsen, MD · Contact
  • Zealand University Hospital
    Roskilde, Denmark
    Recruiting
    • Kirstine Møller Gliese, MD · Contact
  • Dialysis Center DaVita
    Düsseldorf, Germany
    Recruiting
    • Thilo Krueger, MD · Contact
  • Ospedale Madonna del Soccorso
    Ascoli Piceno, Italy
    Recruiting
    • Matthias Zeiler, MD · Contact
  • Ospedale Santa Maria Annunziata
    Bagno a Ripoli, Italy
    Not yet recruiting
    • Rossella Cannavò, MD · Contact
  • Azienda Universitaria Ospedaliera di Bari
    Bari, Italy
    Recruiting
    • Loreto Gesualdo, MD · Contact
  • ASST Spedali Civili di Brescia
    Brescia, Italy
    Not yet recruiting
    • Federico Alberici, MD · Contact
  • Ospedale SS. Annunziata
    Chieti, Italy
    Recruiting
  • IRCCS Policlinico San Martino
    Genova, Italy
    Not yet recruiting
    • Francesca Cappadona, MD · Contact
  • Ospedale Civile San Salvatore
    L’Aquila, Italy
    Recruiting
    • Luca Piscitani, MD · Contact
  • ASST Fatebenefratelli-Sacco -Ospedale Luigi Sacco
    Milan, Italy
    Recruiting
    • Maurizio Gallieni, MD · Contact
  • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
    Milan, Italy
    Not yet recruiting
    • Luca Nardelli, MD · Contact
  • Azienda Ospedaliera Universitaria di Modena
    Modena, Italy
    Recruiting
    • Gabriele Donati, MD · Contact
  • AOU Università degli studi della Campania
    Naples, Italy
    Recruiting
    • Francesco Trepiccione, MD · Contact
  • Università della Campania L.Vanvitelli
    Naples, Italy
    Recruiting
    • Silvio Borrelli, MD · Contact
  • Azienda Ospedaliera di Padova
    Padova, Italy
    Not yet recruiting
    • Anna Bass, MD · Contact
  • Ospedale AUSL "Guglielmo da Saliceto"
    Piacenza, Italy
    Recruiting
    • Roberto Scarpioni, MD · Contact
  • Ospedale S.Eugenio
    Roma, Italy
    Not yet recruiting
    • Roberto Palumbo, MD · Contact
  • Ospedale C. e G. Mazzoni
    San Benedetto del Tronto, Italy
    Recruiting
    • Matthias Zailer, MD · Contact
  • Azienda Ospedaliera Terni
    Terni, Italy
    Recruiting
    • Luigi Vecchi, MD · Contact
  • Ospedale San Giovanni Bosco
    Torino, Italy
    Recruiting
    • Dario Roccatello, MD · Contact
  • Azienda Ospedaliera Universitaria Integrata di Verona
    Verona, Italy
    Recruiting
    • Giovanni Gambaro, MD · Contact
  • University Hospital A Coruña Fundación Profesor Novoa Santos
    A Coruña, Spain
    Recruiting
    • Miguel Perez Fontan, MD · Contact
  • Hospital U. Germans Trias i Pujol
    Badalona, Spain
    Recruiting
    • Marie Troya Saborido, MD · Contact
  • Fundaciòn Puigvert
    Barcelona, Spain
    Recruiting
    • Maria Alba Herreros, MD · Contact
  • Hospital Universitario Josep Trueta
    Girona, Spain
    Recruiting
    • Claudia Castillo Devia · Contact
  • Fundacion Jimenez Diaz
    Madrid, Spain
    Recruiting
    • Catalina Cleary, MD · Contact
  • Hospital Ramón y Cajal
    Madrid, Spain
    Not yet recruiting
    • Haridian Sosa Barrios, MD · Contact
  • Hospital Universitario La Paz
    Madrid, Spain
    Recruiting
    • Maria Bajo, MD · Contact
  • Hospital Universitario Central De Asturias
    Oviedo, Spain
    Recruiting
    • Marie Rodriguez Suarez, MD · Contact
  • Halland County Hospital of Halmstad
    Halmstad, Sweden
    Recruiting
    • Karl Bjurström, MD · Contact
  • Karolinska University Hospital
    Stockholm, Sweden
    Recruiting
    • Olof Heimbürger, MD · Contact
  • Heartlands Hospital
    Birmingham, United Kingdom
    Recruiting
    • Jyoti Baharani, MD · Contact
  • St Luke's Hospital
    Bradford, United Kingdom
    Recruiting
    • Ahsan Syed, MD · Contact
  • University Hospitals Sussex
    Brighton, United Kingdom
    Recruiting
    • Sarah Lawman, MD · Contact
  • Kent and Canterbury Hospital
    Canterbury, United Kingdom
    Recruiting
    • Nilesh Kumar Shah, MD · Contact
  • Hammersmith Hospital
    London, United Kingdom
    Recruiting
    • Richard Corbett, MD · Contact
  • Churchill Hospital
    Oxford, United Kingdom
    Recruiting
    • Udaya Udayaraj, MD · Contact
  • Sheffield Kidney Institute
    Sheffield, United Kingdom
    Recruiting
    • Martin Wilkie, MD · Contact
  • University Hospitals of North Midlands
    Stoke-on-Trent, United Kingdom
    Recruiting
    • Mark Lambie, MD · Contact
08

References and documents

Publications

  • Bonomini M, Davies S, Kleophas W, Lambie M, Reboldi G, Liberato LD, Divino-Filho JC, Heimburger O, Ortiz A, Povlsen J, Iacobelli M, Prosdocimi T, Arduini A. Rationale and design of ELIXIR, a randomized, controlled trial to evaluate efficacy and safety of XyloCore, a glucose-sparing solution for peritoneal dialysis. Perit Dial Int. 2025 Jan;45(1):17-25. doi: 10.1177/08968608241274106. Epub 2024 Aug 28. PubMed 39205396 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2022 (actual). Primary completion is estimated for Dec 2026, 48 months after the start.

Of 42 industry-sponsored phase 3 interventional studies under Kidney Failure, Chronic, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 40. This study's planned 48 months is above that.

Counting every sponsor, half of 66 studies reached it within 32 months; a quarter within 21 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 19, 2019
First posted
Jun 21, 2019
StartActual
Dec 14, 2022
Primary completionEst.
Dec 31, 2026
CompletionEst.
Apr 28, 2027
Last update
Mar 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03994471
Lead sponsor
Iperboreal Pharma Srl
Responsible party
Sponsor
First posted
Jun 21, 2019
Start date
Dec 14, 2022
Primary completion
Dec 31, 2026 (estimated)
Completion
Apr 28, 2027 (estimated)
Last update
Mar 24, 2026

Study contacts

Arduino Arduini, MD
Contact
a.arduini@iperboreal.com
+39.333.6409595
Arduino Arduini, MD
study director · Iperboreal Pharma
Werner Kleophas, MD
study chair · DaVita Deutschland AG

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion